Japan delays market entry for new breast cancer and diabetes drugs due to pricing disputes

The Japanese Ministry of Health, Labour and Welfare has delayed the launch of new breast cancer and diabetes treatments following disagreements with manufacturers over government-mandated pricing. This move highlights ongoing friction between pharmaceutical firms and regulators regarding the sustainability of Japan's national health insurance reimbursement system.